Table 1 Distribution of patients by risk group based on Gleason score.

From: Role of circulating MicroRNAs in prostate cancer diagnosis and risk stratification in the MCC Spain study

Group of analysis

Number of patients (Percentage)

Control Group

54 (21.01%)

Low Risk Group (Gleason score less than 7)

42 (16.34%)

Intermediate Risk Group (Gleason score equal to 7)

110 (42.80%)

High Risk Group (Gleason score greater than 7)

51 (19.84%)